TY - JOUR
T1 - Transfusion-related immunomodulation
T2 - review of the literature and implications for pediatric critical illness
AU - for the Pediatric Critical Care Blood Research Network (Blood Net)
AU - Muszynski, Jennifer A.
AU - Spinella, Philip C.
AU - Cholette, Jill M.
AU - Acker, Jason P.
AU - Hall, Mark W.
AU - Juffermans, Nicole P.
AU - Kelly, Daniel P.
AU - Blumberg, Neil
AU - Nicol, Kathleen
AU - Liedel, Jennifer
AU - Doctor, Allan
AU - Remy, Kenneth E.
AU - Tucci, Marisa
AU - Lacroix, Jacques
AU - Norris, Philip J.
N1 - Publisher Copyright:
© 2016 AABB
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Transfusion-related immunomodulation (TRIM) in the intensive care unit (ICU) is difficult to define and likely represents a complicated set of physiologic responses to transfusion, including both proinflammatory and immunosuppressive effects. Similarly, the immunologic response to critical illness in both adults and children is highly complex and is characterized by both acute inflammation and acquired immune suppression. How transfusion may contribute to or perpetuate these phenotypes in the ICU is poorly understood, despite the fact that transfusion is common in critically ill patients. Both hyperinflammation and severe immune suppression are associated with poor outcomes from critical illness, underscoring the need to understand potential immunologic consequences of blood product transfusion. In this review we outline the dynamic immunologic response to critical illness, provide clinical evidence in support of immunomodulatory effects of blood product transfusion, review preclinical and translational studies to date of TRIM, and provide insight into future research directions.
AB - Transfusion-related immunomodulation (TRIM) in the intensive care unit (ICU) is difficult to define and likely represents a complicated set of physiologic responses to transfusion, including both proinflammatory and immunosuppressive effects. Similarly, the immunologic response to critical illness in both adults and children is highly complex and is characterized by both acute inflammation and acquired immune suppression. How transfusion may contribute to or perpetuate these phenotypes in the ICU is poorly understood, despite the fact that transfusion is common in critically ill patients. Both hyperinflammation and severe immune suppression are associated with poor outcomes from critical illness, underscoring the need to understand potential immunologic consequences of blood product transfusion. In this review we outline the dynamic immunologic response to critical illness, provide clinical evidence in support of immunomodulatory effects of blood product transfusion, review preclinical and translational studies to date of TRIM, and provide insight into future research directions.
UR - http://www.scopus.com/inward/record.url?scp=84994910669&partnerID=8YFLogxK
U2 - 10.1111/trf.13855
DO - 10.1111/trf.13855
M3 - Review article
C2 - 27696473
AN - SCOPUS:84994910669
SN - 0041-1132
VL - 57
SP - 195
EP - 206
JO - Transfusion
JF - Transfusion
IS - 1
ER -